RecruitingNCT07497867

Long-term Prospective Study of Korean CADASIL Patients

Long-term Prognosis of Korean Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy(CADASIL) Patients: A Multicenter Prospective Study


Sponsor

Jeju National University Hospital

Enrollment

500 participants

Start Date

Jul 10, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

K-CADASIL is a 10-year prospective study of 500 Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic brain disease that causes stroke and dementia. The investigators will track symptoms, brain scans, memory tests, and gene information to understand disease progression in Koreans and identify better treatments. Participants will visit clinics regularly for check-ups and blood tests. This study aims to help improve care for CADASIL patients and families worldwide.


Eligibility

Min Age: 19 Years

Inclusion Criteria3

  • Age ≥ 19 years
  • CADASIL suspected or confirmed by genetic testing (NOTCH3 mutation)
  • Able to provide written informed consent (participant or legally authorized representative)

Exclusion Criteria2

  • Contraindication to MRI (claustrophobia, metal implants, pacemaker)
  • Acute ischemic or hemorrhagic stroke within 180 days prior to enrollment

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Jeju National University Hospital

Jeju City, Jeju-do, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07497867


Related Trials